Ocular Therapeutix (OCUL) Long-Term Debt Issuances (2017 - 2019)
Ocular Therapeutix (OCUL) recorded quarterly Long-Term Debt Issuances of -$70000.0 in Q2 2019, down 100.19% quarter-over-quarter from $37.3 million in Q1 2019.
Ocular Therapeutix (OCUL) Long-Term Debt Issuances (2017 - 2019) Analysis & Trends
Ocular Therapeutix's Long-Term Debt Issuances history runs 2 years deep, the most recent figure standing at -$70000.0 for Q2 2019.
- In Q2 2019, Long-Term Debt Issuances changed N/A year-over-year to -$70000.0; the TTM figure through Sep 2021 stood at -$70000.0 (changed N/A YoY), while the FY2023 annual figure was $82.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances was -$70000.0 for Q2 2019 at Ocular Therapeutix, down from $37.3 million in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $37.3 million in Q1 2019 to a low of -$70000.0 in Q2 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.73 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | -70,000.00 |
| Jun 30, 2019 | -70,000.00 |
| Mar 31, 2019 | 37.35 Mn |
| Mar 31, 2019 | 37.35 Mn |
| Mar 31, 2017 | 3.70 Mn |
| Mar 31, 2017 | 3.70 Mn |